As of October, newly FDA-designated "breakthrough" medical devices no longer qualify for two supplementary Medicare payment pathways that have eased commercial uptake since 2020, under a final rule the Centers for Medicare and Medicaid Services issued in August.

What did CMS change?

The August rule finalized removal of regulatory shortcuts that, since 2020, let devices carrying an FDA breakthrough designation obtain new technology add-on payments (NTAP) for inpatient cases and transitional pass-through payments for outpatient cases.

Under the old pathway, manufacturers did not have to demonstrate a "substantial clinical improvement" over existing alternatives or prove the device was new. CMS has now reinstated both requirements. Devices must clear the standard review committees that other new technologies face.

The change affects both inpatient claims, handled through NTAP, and outpatient claims routed via transitional pass-through — two payment streams that, for many breakthrough products, accounted for the bulk of early hospital revenue.

Why did the pathway exist?

The 2020 workaround addressed a chronic gap between FDA marketing clearance and the assignment of a Medicare billing code. Breakthrough designation signals treatment for an unmet need, and the payment guarantees defused a chicken-and-egg problem that routinely stalled adoption.

Clinicians were reluctant to use devices without reimbursement, while manufacturers could not fund the evidence generation needed to earn a code. CMS and Congress treated the automatic add-on as bridge financing — short-term subsidy that bought post-market study time while keeping hospital procurement lines open.

Which devices just made the list?

The September wave arrived days before the cutoff. STAT's Breakthrough Device Tracker logs the recent designations across several categories:

• Triage algorithms that flag critical findings on abdominal CT scans
• Multiplex diagnostic panels for urinary tract infections
• Thrombectomy robots and other next-generation surgical robotics platforms

The exact count of September decisions is not disclosed in the tracker summary reviewed here.

What does the longer record show?

Since 2022, the STAT tracker has captured nearly 800 devices manufacturers reported as holding breakthrough designation at some point. The data is self-reported by manufacturers, not independently audited by FDA or CMS, which limits the precision of any conversion-rate analysis.

Conversion rates from breakthrough status to full FDA approval, or from approval to traditional Medicare reimbursement, are not broken out in the public record.

That gap matters for R&D planning. A breakthrough submission in 2026 no longer pairs with a guaranteed add-on payment, and the historical benchmark for de-risking the designation is no longer publicly available.

What should labs and vendors adjust?

Three operational shifts follow from the August rule:

• Evidence budgets: the substantial-clinical-improvement test has returned, lengthening post-market study timelines and increasing per-device research spend
• Filing sequence: manufacturers that submitted before October can still ride the old rule; later filings face the heavier evidentiary load on every claim
• Sales modeling: revenue forecasts must assume delayed codification rather than automatic add-on income, extending the break-even window for capital-intensive devices

A fourth shift is strategic: the financial value of pursuing breakthrough status at all has fallen, since the speed-to-reimbursement advantage that motivated many submissions has narrowed.

What's next

CMS has not yet published a transition schedule for devices already designated before October but not yet cleared.

The agency's next quarterly NTAP cycle is the first checkpoint to watch. It will determine whether late-arriving 2026 designations can still anchor pass-through claims under the legacy rules — and whether hospital procurement teams drafting 2027 capital plans face a planning vacuum at the moment their submissions need a clear answer.